Cargando…

Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride

INTRODUCTION: A multinational post-authorization safety study assessed cardiovascular safety in initiators of prucalopride for chronic constipation compared with a matched cohort of polyethylene glycol 3350 initiators. The primary safety outcome was major adverse cardiovascular events (MACE), a comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruigómez, Ana, Plana, Estel, Gilsenan, Alicia, Fortuny, Joan, Cainzos-Achirica, Miguel, Flynn, Robert W. V., MacDonald, Thomas M., Garcia-Rodriguez, Luis, Ziemiecki, Ryan, Andrews, Elizabeth B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053159/ https://www.ncbi.nlm.nih.gov/pubmed/33606202 http://dx.doi.org/10.1007/s40264-021-01044-4

Ejemplares similares

Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350
por: Fortuny, Joan, et al.
Publicado: (2019)

Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study
por: Gilsenan, Alicia, et al.
Publicado: (2019)

Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study
por: Forns, Joan, et al.
Publicado: (2022)

Effect of prucalopride on symptoms of chronic constipation
por: Tack, J, et al.
Publicado: (2013)

Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias
por: Kaye, James A., et al.
Publicado: (2017)

The Effects of Prucalopride on Postoperative Ileus in Guinea Pigs
por: Park, Soo Jung, et al.
Publicado: (2013)

Effects of prucalopride on esophageal secondary peristalsis in humans
por: Yi, Chih-Hsun, et al.
Publicado: (2016)

Prucalopride: the evidence for its use in the treatment of chronic constipation
por: Coremans, Georges
Publicado: (2008)

Effect of Prucalopride on the Pharmacokinetics of Oral Contraceptives in Healthy Women
por: Van de Velde, Vera, et al.
Publicado: (2013)

Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands
por: Nuijten, Mark J. C., et al.
Publicado: (2015)

Patient considerations in the management of chronic constipation: focus on prucalopride
por: Shin, Andrea
Publicado: (2016)

Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom
por: Margulis, Andrea V., et al.
Publicado: (2018)

Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation
por: Tameez Ud Din, Asim, et al.
Publicado: (2019)

Polypill for Population-Level Primary Cardiovascular Prevention in Underserved Populations—A Social Epidemiology Counterargument
por: Cainzos-Achirica, Miguel, et al.
Publicado: (2020)

Effects of Single-Dose Prucalopride on Intestinal Hypomotility in Horses: Preliminary Observations
por: Laus, Fulvio, et al.
Publicado: (2017)

Development of a population pharmacokinetic model of prucalopride in children with functional constipation
por: van Schaick, Erno, et al.
Publicado: (2016)

Colon Capsule Visualization Is Not Enhanced with Prucalopride: A Randomized Controlled Trial
por: Hookey, Lawrence, et al.
Publicado: (2018)

Role of Prucalopride in Treating Functional Constipation and Gastroparesis: A Systemic Review
por: Ali, Hassam, et al.
Publicado: (2021)

A Review of the Cardiovascular Safety of Prucalopride in Patients With Chronic Idiopathic Constipation
por: Tack, Jan, et al.
Publicado: (2023)

Cardiovascular risk perception in women: true unawareness or risk miscalculation?
por: Cainzos-Achirica, Miguel, et al.
Publicado: (2015)

Response to letter: Balancing risks and benefits of prucalopride for the treatment of chronic constipation in Asians
por: Ke, M, et al.
Publicado: (2013)

Efficacy of Prucalopride in bowel cleansing before colonoscopy: Results of a pilot study
por: Corleto, Vito Domenico, et al.
Publicado: (2017)

The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies
por: Deding, Ulrik, et al.
Publicado: (2022)

Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
por: Johannes, Catherine B., et al.
Publicado: (2022)

Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
por: Danysh, Heather E., et al.
Publicado: (2022)

The Evolving Landscape of Cardiovascular Disease Prevention
por: Cainzos-Achirica, Miguel, et al.
Publicado: (2021)

The Effect of Prucalopride on Small Bowel Transit Time in Hospitalized Patients Undergoing Capsule Endoscopy
por: Alsahafi, Majid, et al.
Publicado: (2017)

Prucalopride: A Recently Approved Drug by the Food and Drug Administration for Chronic Idiopathic Constipation
por: Mahajan, Rajiv
Publicado: (2019)

Tissue distribution and abuse potential of prucalopride: findings from non-clinical and clinical studies
por: Derakhchan, Katayoun, et al.
Publicado: (2023)

Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation
por: Wong, Banny S, et al.
Publicado: (2010)

Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation
por: Sloots, Cornelius E. J., et al.
Publicado: (2010)

Prucalopride Improves Bowel Function and Colonic Transit Time in Patients With Chronic Constipation: An Integrated Analysis
por: Emmanuel, Anton, et al.
Publicado: (2014)

Prucalopride inhibits the glioma cells proliferation and induces autophagy via AKT-mTOR pathway
por: Qiao, Hong, et al.
Publicado: (2018)

Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials
por: Camilleri, Michael, et al.
Publicado: (2016)

Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and Bayesian analysis
por: Yang, Tao, et al.
Publicado: (2021)

Current Opinion on Prucalopride in Gastroparesis and Chronic Constipation Treatment: A Focus on Patient Selection and Safety
por: Hong, Ji Taek
Publicado: (2021)

Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating
por: Staller, Kyle, et al.
Publicado: (2022)

Prucalopride might improve intestinal motility by promoting the regeneration of the enteric nervous system in diabetic rats
por: Wang, Yun, et al.
Publicado: (2022)

Cardiovascular Disease Prevention During the COVID-19 Pandemic: Lessons Learned and Future Opportunities
por: Duffy, Eamon, et al.
Publicado: (2021)

Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study
por: Smith, William B, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rf8k940mlrq1sr6pj6vqlf6ig6